Current Emerging Therapy for Amyloidosis Neuropathy
Peripheral neuropathy is a typical phenotype based on the problems that happened
at the root of the damaged nerve.
Over 50% of peripheral neuropathy are inherited neurological disorders caused
by several numbers of causative genes, and it usually comes with different levels of phenotype.
Among the peripheral neuropathy, polyneuropathy accounts for the massive amount of cases.
It occurs when there are multiple nerves throughout your body present malfunction.
It has been known that several reasons may cause polyneuropathy, including exposure
to specific toxic or poor nutrition, or due to a side effect from diseases.
The most common symptoms of polyneuropathy are tingling, numbness,
loss of sensation, and a burning sensation in the extremities.
One of the most severe polyneuropathies called Guillain-Barre syndrome, a rare disease that strikes
suddenly when the immune system attacks nerves.
Symptoms tend to appear quickly and worsen rapidly, sometimes leading to paralysis.
Currently, around 20-30% of Americans suffering from peripheral neuropathy.
Although the influence is broadly cross all ages, the older adults are at increased risk.
According to the statistic of peripheral neuropathy, there are 30% of patients
with diabetic peripheral neuropathy 30% of patients with chemotherapy-induced
peripheral neuropathy and around 35% of patients with
the human immunodeficiency virus induced peripheral neuropathy.
Among different factors induced peripheral neuropathy, familial
amyloid polyneuropathy is a peculiar form of peripheral
neuropathy, induced by a genetic mutation.
Hereditary transthyretin amyloidosis is a devastating polyneuropathy
due to amyloid accumulation in the peripheral nervous system.
Both tafamidis and diflunisal are selective TTR stabilizers has been approved for the treatment of
FAP patients with early-onset polyneuropathy to delay neurological impairment.
Neuro Open J. 2020; 7(1): 5-8. doi: 10.17140/NOJ-7-134
